IntraLinks
, a provider of critical information exchange solutions,
announced a partnership
with
SAFE-BioPharma
, the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries. IntraLinks users will now be able to use the SAFE-BioPharma digital identity for signing documents. They can increase clinical trial efficiency by signing paperwork with a SAFE credential that provides additional security and speed, eliminating printing of hard copy casebooks and other documents.
Users will have the opportunity to upload and use their SAFE-BioPharma digital identities on the IntraLinks® platform, ensuring that their credentials are available anywhere via the Web. IntraLinks is also enabling documents signed with SAFE-BioPharma signatures to be stored and shared on its existing platform.
“Incorporating SAFE-BioPharma’s digital identity and signature standard into IntraLinks’ platform is very significant for our clients and the community who rely on IntraLinks to manage their clinical trial communication and document exchange,” said Alison Shurell, VP, life sciences product marketing, IntraLinks. “In addition to already being able to securely upload, receive, review and distribute documents on IntraLinks, sponsors, CROs and investigators will soon be able to eliminate the need to print out or physically store the numerous documents that require signatures during a clinical trial."
In addition to incorporating the digital signature into its platform, IntraLinks has joined the SAFE-BioPharma vendor partner community.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.